L3VLUP
ProSign in

TARS · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TARSAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TARS
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterTARSAMGN
Q3 2020none listed holders, n.a.16 holders, $16.3bn
Q4 2020none listed holders, n.a.19 holders, $14.0bn
Q1 20211 holders, $397k16 holders, $14.5bn
Q2 2021none listed holders, n.a.23 holders, $13.8bn
Q3 2021none listed holders, n.a.24 holders, $11.6bn
Q4 2021none listed holders, n.a.21 holders, $10.4bn
Q1 2022none listed holders, n.a.23 holders, $9.9bn
Q2 2022none listed holders, n.a.28 holders, $9.7bn
Q3 2022none listed holders, n.a.21 holders, $7.9bn
Q4 2022none listed holders, n.a.24 holders, $9.3bn
Q1 2023none listed holders, n.a.22 holders, $8.4bn
Q2 2023none listed holders, n.a.26 holders, $7.4bn
Q3 20232 holders, $14m26 holders, $8.7bn
Q4 20232 holders, $13m24 holders, $8.4bn
Q1 20242 holders, $31m25 holders, $6.7bn
Q2 20242 holders, $35m20 holders, $8.0bn
Q3 20245 holders, $62m21 holders, $8.8bn
Q4 20244 holders, $46m20 holders, $8.2bn
Q1 20251 holders, $31m25 holders, $12.0bn
Q2 20253 holders, $98m20 holders, $10.2bn
Q3 20253 holders, $122m17 holders, $10.4bn
Q4 20254 holders, $202m19 holders, $18.0bn
Q1 20264 holders, $184m15 holders, $21.4bn
Q2 20264 holders, $201m23 holders, $24.9bn
TARS

Tarsus Pharmaceuticals Inc

Holders
2
Reported value
$13m
Buyers
0
Sellers
2

Breadth -2 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
24
Reported value
$8.4bn
Buyers
14
Sellers
11

Breadth +3 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2023

Among the 26 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only TARS (2)

Artisan Partners LP, ExodusPoint Capital Management LP

Only AMGN (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Moore Capital Management LP, Neuberger Berman Group LLC, PDT Partners LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →